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Abbreviations 
heart transplant = HT 
routine surveillance biopsy = RSB 
International Society for Heart and Lung Transplantation = ISHLT 
congenital heart disease = CHD 
confidence interval = CI 
odds ratio = OR 
hazard ratio = HR 
Pediatric Heart Transplant Society = PHTS 
antibody mediated rejection = AMR 
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ABSTRACT 
 
Due to limited and conflicting data in pediatric patients, long-term routine surveillance 
endomyocardial biopsy (RSB) in pediatric heart transplant (HT) remains controversial. We 
sought to characterize the rate of positive RSB and determine factors associated with RSB-
detected rejection. Records of patients transplanted at a single institution from 1995-2015 with 
>2y of post-HT biopsy data were reviewed for RSB-detected rejections occurring >2y post-HT. 
We illustrated the trajectory of significant rejections (ISHLT Grade ≥3A/2R) among total RSB 
performed over time and used multivariable logistic regression to model the association 
between time and risk of rejection. We estimated Kaplan-Meier freedom from rejection rates by 
patient characteristics and used the log-rank test to assess differences in rejection probabilities. 
We identified the best-fitting Cox proportional hazards regression model. In 140 patients, 86% 
did not have any episodes of significant RSB-detected rejection >2y post-HT. The overall 
empirical rate of RSB-detected rejection >2y post-HT was 2.9/100 patient-years. The 
percentage of rejection among 815 RSB was 2.6% and remained stable over time. Years since 
transplant remained unassociated with rejection risk after adjusting for patient characteristics 
(OR=0.98; 95% CI 0.78-1.23; p=0.86). Older age at HT was the only factor that remained 
significantly associated with risk of RSB-detected rejection under multivariable Cox analysis 
(p=0.008). Most pediatric patients did not have RSB-detected rejection beyond 2 years post-HT 
and the majority of those who did were older at time of HT. Indiscriminate long-term RSB in 
pediatric heart transplant should be reconsidered given the low rate of detected rejection. 
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BACKGROUND 
First described by Dr. Caves in 1973,1 the percutaneous, transvenous endomyocardial biopsy 
remains the gold standard for monitoring allograft rejection after heart transplant (HT).2 There 
are still, however, many disadvantages of this test including high cost,3 patient discomfort and 
inconvenience, rare risk of serious complication,4 and subjective interpretation of findings.5
 
  
Both adult and pediatric heart transplant recipients are at the highest risk for rejection early after 
HT.6-8 Based on the rare risk of late rejection (mostly ranging between 1.6-3.7%), most adult 
studies have supported discontinuing routine surveillance biopsy (RSB) 1-2 years after 
transplant in standard risk patients.3, 6, 9-23 In pediatric studies, late rejection is an important 
finding as it has been associated with decreased graft survival.24, 25 The rate of rejection found 
by RSB in the 2nd year and beyond post-HT is significantly more variable, ranging anywhere 
from 0 to 12%.7, 8, 24-35
 
 These previous studies (from before 2000) may not reflect current 
practices and risk and generally did not assess the possible time-related risk of late rejection. 
Due to the conflicting historical data and the absence of contemporary studies in pediatric heart 
recipients, the practice of long-term RSB in pediatric HT remains controversial.  
The primary aims of this study were (1) to characterize the observed rate of positive routine 
surveillance endomyocardial biopsy in order to assess long-term surveillance protocol 
performance (beyond 2 years post-HT) and (2) to determine risk factors associated with 
surveillance-detected rejection.  
 
METHODS 
Study population 
The inception cohort for this study included HT patients from a pediatric heart transplant center 
with demographic and post-transplant biopsy history available from institutional electronic health 
records from January 1995 through July 2015. In order to assess the relationship of early 
rejection to later rejection risk, we excluded patients with no recorded biopsy results within their 
first 60 days of transplant. Given our specific aims, we excluded patients who did not have at 
least 2 full years of post-HT biopsy data. We also excluded retransplant recipients. Further 
details regarding transplant outcomes in this cohort have been previously reported.36
 
 The study 
was approved by the Institutional Review Board.  
Induction and Maintenance Immunosuppression 
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Standard protocol consisted of induction with methylprednisolone intraoperatively and either 
daclizumab, basiliximab or rabbit anti-thymoglobulin. Post-operatively, patients received 
maintenance immunosuppressive therapy consisting of a calcineurin inhibitor (cyclosporine or 
tacrolimus), mycophenolate mofetil, and methylprednisolone or prednisone, which was tapered 
over the first post-transplant year. Cyclosporine and tacrolimus dosing were modulated to 
achieve target troughs of 300-350 or 10-12 g/dl, respectively, for the first 3 post-transplant 
months, after which doses were adjusted downward sequentially to maintenance goal troughs of 
175-225 g/dl for cyclosporine or 5-7 g/dl for tacrolimus at >24 months post-transplant. Select 
patients were transitioned to sirolimus at various time points at least 6 months post-transplant 
and were dosed to achieve a target trough of 6-8 g/dl and continued on reduced-dose 
cyclosporine or tacrolimus adjusted to achieve target troughs of 100-150 or 2-4 g/dl, 
respectively.  
 
Outcome 
Biopsies were classified according to the ISHLT 1990 criteria,37 a standardized grading system 
to diagnose acute cellular rejection developed by the International Society for Heart and Lung 
Transplantation (ISHLT). We considered grades 0 and 1A as “negative for rejection” and 1B and 
2 as “mild rejection.” Grades 3A, 3B and 4 (equivalent to 2R-3R rejection using the revised 2004 
grading scheme38
 
) were classified as “clinically significant rejection.”  
Per institutional protocol, after 2 years post-transplant, surveillance biopsies have been routinely 
performed every 6 months during the study period irrespective of age. However, biopsies were 
often performed more frequently than every 6 months in patients perceived to be at higher risk 
for rejection or require heightened surveillance. For example, earlier or more frequent biopsies 
were performed in patients to follow up a rejection episode, with history of recurrent rejection, 
with other clinical concern for rejection, after significant changes in immunosuppression, with 
nonadherence and at the discretion of the team. It was not always clearly defined whether the 
more frequent biopsies were performed for regular, heightened surveillance, to follow up a 
rejection episode, or for active concern for new rejection. Thus, all biopsies performed earlier 
than the protocol guidelines were considered “non-routine.” In order to focus the analysis on 
only routine, standard risk biopsies and assess the performance of an ongoing biannual RSB 
schedule, only biopsies occurring at least 4.5 months (135 days) after the previous biopsy were 
considered RSB.  
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Statistical analysis 
We presented baseline demographics at the time of HT, as well as early rejection history (years 
0-2 post-HT), by highest achieved 1990 ISHLT grade category during follow-up (beyond Year 
2). Categorical variables were summarized as counts and percentages, and continuous 
variables were summarized as median with first and third quartiles (Q1,3). Age at transplant and 
transplant era were categorized based on previously used thresholds.39
 
  
To characterize the rate of positive RSB in our time trend analysis, we first calculated and 
graphed the percentage of clinically significant rejections among total RSB performed from Year 
2 to Year 10 post-transplant, overall and also stratified by age group at HT. We then fit a 
multivariable logistic regression model to relate the log odds of identifying ISHLT grade of 3A or 
above to time since Year 2 of transplant, while accounting for transplant era, age at transplant, 
gender, congenital heart disease (CHD) diagnosis, and history of rejection, as captured by 
baseline rejection status and cumulative number of biopsies at ISHLT grade 3A or above during 
follow-up. Fractional polynomial regression, implemented via the mfp R package (version 1.5.2, 
R Foundation for Statistical Computing, Vienna, Austria), was used to select the best functional 
form for modeling time. We estimated Huber-White standard errors to account for within-subject 
correlation and used them to construct 95% confidence intervals (CI) for estimated odds ratios 
(OR).  
 
To determine risk factors associated with surveillance-detected rejection, we estimated Kaplan-
Meier freedom from rejection rates by patient characteristics and used the log-rank test to 
assess differences in survival probabilities. We then used exhaustive search model selection, 
implemented via the glmulti R package (version 1.0.7), to identify the Cox proportional hazards 
regression model among all possible models that minimized the Akaike information criterion and 
presented estimated hazard ratios (HR) and associated 95% confidence intervals (CIs) from this 
model. In these analyses, we considered as the outcome time to each patient’s first occurrence 
of grade ≥3A rejection during follow-up, censored at each patient’s date of last biopsy or death. 
Statistical significance was assessed at the 0.05 level, and all analyses were performed in the R 
statistical computing framework (version 3.3). 
 
26 
RESULTS 
Of 230 pediatric patients with both demographic and post-HT biopsy history available in the 
electronic medical record, 10 who did not have recorded biopsy results within the first 60 days 
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post-HT and 80 others who did not have at least 2 years of post-HT follow-up were excluded (35 
patients were transplanted within 2 years of the analysis, 25 patients died within 2 years post-
HT and another 20 did not have a full 2 years of follow-up for other reasons). This yielded an 
analytic cohort of 140 patients (Figure 1). Baseline demographics for the analytic cohort are 
shown in Table 1. Approximately half of the patients were male, and 38% were of white race. 
The median age at transplant was 10.6 (Q1,3: 2.3, 14.6) years. Approximately one-third of the 
patients had CHD and the majority (64%) were transplanted in 2004 or later.  
 
The 140 study patients underwent a total of 1916 biopsies beyond 2 years post-HT, of which 
815 (43%) were RSB. The median number of follow-up RSB per patient was 5 (Q1,3: 3, 9). 
Patients were followed for a total of 714.5 years, with median duration of follow-up 4.6 (Q1, 3: 
2.6, 7.5) years. Most patients (86%) did not have any episodes of clinically significant rejection 
(≥3A by 1990 ISHLT grade) detected by RSB beyond 2 years post-HT. Characteristics of 
patients who did and did not have late rejection on RSB are summarized in Table 1.  
 
The overall empirical rate of rejection detected by RSB after 2 years was 2.9 per 100 patient-
years. The percentage of rejections among RSB was 2.6% and remained relatively stable over 
time (Figure 2a). Follow-up rejection patterns differed by age at HT (Figure 2b). In all children 
aged 2 or less at HT, there was a single rejection episode, which occurred in the third year post-
HT. Four total rejection episodes were detected in the cohort between ages 2 and 13 at HT. In 
patients over age 13 at HT, the annual rate of rejection by RSB was higher, ranging from 0 to 
15% over time. 
 
After fitting a Cox proportional hazards model with adjustment for transplant era, age at 
transplant, gender, CHD diagnosis, and history of rejection, time since HT—remained 
unassociated with rejection by RSB (OR=0.98; 95% CI 0.78-1.23; p=0.86, Table 2). The same 
model showed that patients over age 13 years at HT were significantly more likely to have 
rejection diagnosed by RSB compared with patients aged 2 years or less (p=0.03).  
 
Kaplan-Meier curves depicting time to first grade ≥3A rejection by levels of patient 
characteristics are shown in Figure 3. Log-rank analysis identified age category at HT and CHD 
diagnosis as factors univariately associated with time to first occurrence of clinically significant 
rejection by RSB. Exhaustive search over all patient characteristics in Table 1 yielded the same 
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two factors, and age category at HT was the only one that remained significantly associated 
with risk of rejection under multivariable Cox analysis (p=0.008, Table 3).  
 
DISCUSSION 
This study demonstrates that most pediatric patients transplanted at our center between 1995 
and 2015 did not have significant rejection detected by RSB beyond 2 years after HT. The 
overall rate of rejection detected by RSB after 2 years was 2.9 per 100 patient-years. Older age 
at HT was the only factor associated with increased rejection detected by RSB on multivariable 
analysis. The rate of rejection by RSB did not change across transplant eras or decrease over 
time after transplant (within 10 years) in the study cohort.  
 
A recent Pediatric Heart Transplant Society (PHTS) analysis showed that RSB detected 81.6% 
of the reported rejection episodes.26
  
 However, since the PHTS does not collect the number of 
biopsies performed, the report could not provide the yield of RSB or address how frequently 
RSB should be performed. This updated pediatric study, which includes data and practices from 
the earliest era to the current, is the first to specifically investigate the utility and yield of a typical 
long-term surveillance biopsy protocol and identify factors associated with cellular rejection 
detected by RSB. Additionally, this time-related analysis is unique in that it utilized fractional 
polynomial methodology to determine the most appropriate functional form for modeling time, 
which allowed us to avoid assuming any particular trajectory, linear or otherwise for rejection 
over time. 
There have not been any contemporary pediatric studies of RSB performance using data after 
2000. Consistent with earlier studies, our analysis confirms that RSB is exceedingly low yield in 
patients transplanted as infants.32, 33 There was only a single episode of rejection by RSB 
detected in patients ≤2 years-old at the time of HT, occurring during the third year post-HT. In 
children transplanted between 2 and 13 years of age, the rate of rejection detected by RSB was 
also exceedingly low. On the other hand, late rejection detected by RSB was higher in patients 
>13 years-old at HT. This finding is consistent with previous PHTS studies that have 
demonstrated older age to be a risk factor for both late rejection and rejection with severe 
hemodynamic compromise.8, 24 In older patients, we hypothesize that differences in 
immunology, nonadherence and psychosocial stressors, donor-related factors and other 
unknown influences may potentially contribute to the higher persistent risk of rejection, even late 
post-HT.   
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In combination with prior reports, the current study shows that long-term (beyond 2 years post-
HT) RSB for asymptomatic acute cellular rejection is low-yield, and suggests that RSB is not 
clearly indicated in younger children, especially those aged 2 years or less at HT. In older 
patients, our data suggests that ongoing surveillance may be warranted. Previous studies have 
shown that earlier era, previous rejection, and non-white race were associated with a higher risk 
of rejection.24, 25 These factors were not associated with risk for rejection in this single-center 
analysis, which focused only on RSB and intentionally omitted patients at higher perceived risk 
who received more frequent biopsies. Rejection episodes detected by clinically indicated 
biopsies (performed more frequently than standard protocol) were not included in the analysis. 
Not unexpectedly, the number of early rejection episodes (within 2 years post-HT) in our cohort 
is lower than what has been previously described.8
    
 If early rejecters were placed back on 
standard surveillance protocol, presumably due to clinical stability, they were not at higher risk 
for a positive RSB in our data.  
Unexpectedly, there was a trend towards lower rate of rejection in patients with CHD. This 
borderline association most likely reflects the fact that the CHD patients were younger at the 
time of HT (median age 7.5 years vs 11.4 years) and younger age at HT is associated with 
decreased rejection. The association of CHD with rejection risk was no longer significant in 
multivariable analysis that included age.  
 
In this analysis, more than half of the biopsies were obtained more frequently than required by 
the protocol. At our center, patients often received additional biopsies for immunosuppression 
changes, rejection follow up, history of recurrent rejection, noncompliance and, of course, 
clinical concern for rejection. We intentionally excluded these biopsies to specifically analyze the 
routine, standard risk biopsies.  
 
Limitations 
There are limitations to this study. The data were from a single center. However, current 
multicenter registry data do not capture the granularity necessary to answer the questions 
posed by our study. Relatedly, because the number of patients and events are relatively small in 
this single center analysis, we cannot draw definitive conclusions and make large-scale practice 
changes based on the findings. The analysis also excluded 20 patients who did have complete 
2 years of follow up for unclear reasons which may have introduced bias into the findings. In 
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addition, there may have been some misclassification of biopsies as routine (i.e., a biopsy 
performed ≥4.5 months after the previous biopsy may have been “non-routine” or clinically 
indicated). However, we believe this was the most consistent and straightforward way to classify 
biopsies, as the documentation was not always explicit and our institutional protocol called for a 
biopsy to be performed biannually after 2 years post-HT. This classification scheme also 
enabled us to analyze the performance of a commonly performed biopsy protocol. Since 
clinically indicated, non-RSB are expected to have higher detection rates, misclassification of 
non-RSB as RSB would be expected to produce an overestimate of the rate of detection with 
RSB. The true rejection rates with RSB may be even lower than described. We acknowledge 
that these data may not include some biopsies performed in the highest risk patients, who were 
likely biopsied more frequently than every half year. This study intentionally focused on the 
utility of long-term RSB in otherwise standard risk patients and did not attempt to address the 
issue of what should be done in patients deemed to be at higher risk for rejection.  
 
We recognize that patients often undergo biopsy for cellular rejection as part of their regular 
follow up cardiac catheterization that also includes screening for antibody mediated rejection, 
evaluating for cardiac allograft vasculopathy and assessing hemodynamics. We elected to not 
include antibody mediated rejection (AMR) in our analysis since much of our data predates 
standard AMR pathologic classifications. However, we have recently reported our center’s 
recent AMR outcomes which demonstrated an exceedingly low incidence of ≥pAMR 2 
biopsies.40 Especially for patients in whom long-term routine biopsy is likely low-yield, 
noninvasive methods of surveillance for vasculopathy and graft function deserve further study 
and consideration.41
 
  
CONCLUSION 
Most pediatric patients do not have significant rejection detected by routine surveillance biopsy 
beyond 2 years after heart transplant. Indiscriminate long-term routine surveillance biopsy in 
pediatric heart transplant should be reexamined given the low rate of detected rejection. Age at 
transplant may be an important consideration when determining patient-specific long-term 
surveillance plans. Prospective evaluation of different long-term surveillance strategies may be 
warranted.  
 
 
None of the authors have any relevant disclosures. This project was not funded.  
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Figure 1. CONSORT diagram of pediatric heart transplant study population. 
 
Figure 2a. Total number of post-transplant routine biopsies (histogram) and percent of grade 
≥3A routine biopsies (line) during follow-up, truncated at Year 10 due to subsequent low counts. 
 
Figure 2b. Total number of post-transplant routine biopsies (histogram) and percent of grade 
≥3A routine biopsies (line) during follow-up, truncated at Year 10 due to subsequent low counts, 
stratified by transplant age categories. 
 
Figure 3. Kaplan-Meier curves for time to first grade ≥3A rejection during follow-up beyond two 
years post-transplant by levels of baseline characteristics, truncated at Year 10.  
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Table 1. Baseline characteristics of N=140 patients by highest rejection grade identified beyond two years post-HT. 
 
  
Overall 
(N=140) 
None or  
Mild Rejectiona 
 (N=121) 
Clinically Significant 
Rejectionb 
(N=19) 
 n (%) n (%) n (%) 
Demographics    
Male  77 (55.0) 65 (53.7) 12 (63.2) 
Patient Race    
White 53 (37.9) 46 (38.0) 7 (36.8) 
Black 9 (6.4) 8 (6.6) 1 (5.3) 
Other† 34 (24.3) 30 (24.8) 4 (21.1) 
Unknown 44 (31.4) 37 (30.6) 7 (36.8) 
Age at Transplant, years  
(median, Q1,3) 
 
10.6 (2.3, 14.6) 9.8 (2.1, 14.1) 14.8 (11.6, 15.7) 
Age Group at Transplant    
0-2 31 (22.1) 30 (24.8) 1 (5.3) 
>2-13 58 (41.4) 52 (43.0) 6 (31.6) 
>13-23 51 (36.4) 39 (32.2) 12 (63.2) 
Transplant Era    
1994-2003 51 (36.4) 39 (32.2) 12 (63.2) 
2004-2008 50 (35.7) 47 (38.8) 3 (15.8) 
2009-2013 39 (27.9) 35 (28.9) 4 (21.1) 
CHD Diagnosis 46 (32.9) 44 (36.4) 2 (10.5) 
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Highest Baseline‡ Rejection 
Grade 
 
  
Grade 1A 75 (53.6) 66 (54.5) 9 (47.4) 
Grade 1B 3 (2.1) 2 (1.7) 1 (5.3) 
Grade 2 19 (13.6) 15 (12.4) 4 (21.1) 
Grade ≥3A 37 (26.4) 32 (26.4) 5 (26.3) 
         
†Other race includes Asian, Latino, and Native American. ‡Within first 2 years post-heart transplant. a1990 Grade ≤ 2. b1990 Grade ≥ 3A  
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Table 2. Estimated ORs with robust 95% CIs from multivariable logistic  
regression model to characterize surveillance performance over time. 
 
Covariates OR 95% CI P-value 
Years Since Baseline 0.98 (0.78, 1.23) 0.861 
Transplant Era    
1995-2003 1.00 REF REF 
2004-2008 0.68 (0.12, 3.83) 0.665 
2009-2013 1.53 (0.36, 6.44) 0.559 
Age Group at Transplant    
0-2 years 1.00 REF REF 
>2-13 years 3.25 (0.39, 27.1) 0.277 
>13-23 years 9.87 (1.19, 81.6) 0.034 
Male  0.79 (0.32, 1.94) 0.604 
CHD Diagnosis 0.46 (0.08, 2.53) 0.370 
Cumulative no. of ≥3A Rejections 1.63 (0.86, 3.09) 0.132 
Baseline Rejection Category     
No rejection (0, 1A) 1.00 REF REF 
Mild rejection only (1B, 2)  1.22 (0.35, 4.29) 0.754 
Grade ≥3A rejection  0.74 (0.12, 4.60) 0.750 
 
 
 
 
 
 
 
Table 3. Estimated HRs from multivariable Cox proportional hazards model, based on exhaustive 
search results. 
Covariates HR 95% CI P-value Global P* 
Age at Transplant     
0-2 years 1.00 REF REF 0.008 
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>2-13 years 2.12 (0.25, 17.7) 0.490 
>13-23 years 7.61 (0.99, 58.8) 0.052 
CHD Diagnosis 0.26 (0.06, 1.15) 0.076 0.076 
*Global P-value obtained from likelihood ratio test. 
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